CXL-1020 is a hydroxylamine-based nitro (HNO) donor. CXL-1020 improves myocardial contractility/diastolicity and Ca2+ circulation in rats with diastolic abnormalities. CXL-1020 induces vasodilation and improves cardiac function in canine models. CXL-1020 has been used to study systolic heart failure and stable heart failure.

Physicochemical Properties

Molecular Formula	C7H9NO5S2
Molecular Weight	251.280059576035
Exact Mass	250.992
CAS #	950834-06-7
PubChem CID	52939580
Appearance	White to off-white solid powder
LogP	-0.4
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	3
Heavy Atom Count	15
Complexity	402
Defined Atom Stereocenter Count	0
SMILES	C1(S(NO)(=O)=O)=CC=CC=C1S(C)(=O)=O
InChi Key	RZRWBKKAFHXNEQ-UHFFFAOYSA-N
InChi Code	InChI=1S/C7H9NO5S2/c1-14(10,11)6-4-2-3-5-7(6)15(12,13)8-9/h2-5,8-9H,1H3
Chemical Name	N-hydroxy-2-methylsulfonylbenzenesulfonamide
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vivo	Mice treated with CXL-1020 (100 μg/kg/min; infused over 30 minutes) exhibit improved diastolic and systolic performance as well as improved hemodynamics and cardiac function [1]. In dogs with advanced heart failure, CXL-1020 (3 and 10 mg/kg/min; intravenous infusion lasting 4 hours) improves left ventricular systolic and diastolic function [2].
Animal Protocol	Animal/Disease Models: Adult male SD (SD (Sprague-Dawley)) rat (250-350 g; isoproterenol-induced cardiac dysfunction) [1] Doses: 100 μg/kg/min Administration time: 30 minutes Experimental Results: Improved normal hemodynamics and cardiac function in rats, and enhanced diastolic and systolic performance in mice with cardiac dysfunction. Animal/Disease Models: Dog (coronary microembolism-induced heart failure) [2] 3 and 10 mg/kg/min Doses: 3 and 10 mg/kg/min Route of Administration: 4-hour intravenous (iv) (iv)infusion Experimental Results: Aortic systolic blood pressure (AoP) moderately diminished; Dramatically increased deceleration time in EF and early mitral inflow velocity (DT) and Dramatically diminished left ventricular (LV) end-systolic volume (ESV), left ventricular end-diastolic pressure ( EDP) and end-diastolic wall stress (EDWS)-dependent manner.
References	[1]. CXL-1020, a Novel Nitroxyl (HNO) Prodrug, Is More Effective than Milrinone in Models of Diastolic Dysfunction-A Cardiovascular Therapeutic: An Efficacy and Safety Study in the Rat. Front Physiol. 2017 Nov 10;8:894. [2]. Intravenous Infusion of CXL-1020, a Novel Nitroxyl (HNO) Donor, Improves Left Ventricular Systolic and Diastolic Function in Dogs with Advanced Heart Failure. CARDIOVASCULAR PHARMACOLOGY. VOLUME 15, ISSUE 6, SUPPLEMENT, S73-S74, AUGUS.
Additional Infomation	CXL-1020 is under investigation in clinical trial NCT01092325 (Safety and Hemodynamic Effects and Pharmacokinetics of CXL-1020 in Patients With Stable Heart Failure).

Solubility Data

Solubility (In Vitro)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.9796 mL	19.8981 mL	39.7962 mL
	5 mM	0.7959 mL	3.9796 mL	7.9592 mL
	10 mM	0.3980 mL	1.9898 mL	3.9796 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.